A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...
While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...
This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...
Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to ...
This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.